An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa.

This article outlines some of the barriers to single low-dose (SLD) primaquine use to stop P. falciparum transmission. In-country key informants revealed that the WHO weight-based recommendation to use SLD primaquine is challenging to implement in actual field settings, due in part to safety concerns involving G6PD deficiency and drug-drug interactions, among other factors.

← Back to previous page